Phaseline

Targets › TNFRSF10B

TNFRSF10B (Tumor necrosis factor receptor superfamily member 10B): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. (UniProt, O14763)

Open in Phaseline: the race on TNFRSF10B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Inhibrx BiosciencesINBRX-109
Tetravalent DR5 agonist antibody
TNFRSF10BPhase 2Conventional Chondrosarcoma; Ewing SarcomaDec 2026

Conditions

Conventional Chondrosarcoma (1) Ewing Sarcoma (1)

Modalities

small molecule (1)

Companies

Inhibrx Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.